Vertex Pharmaceuticals PE Ratio 2006-2021 | VRTX

Current and historical p/e ratio for Vertex Pharmaceuticals (VRTX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Vertex Pharmaceuticals PE ratio as of October 22, 2021 is 18.50.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Vertex Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 183.52 24.21
2021-06-30 201.63 $7.58 26.60
2021-03-31 214.89 $10.50 20.47
2020-12-31 236.34 $10.30 22.95
2020-09-30 272.12 $10.23 26.60
2020-06-30 290.31 $7.92 36.66
2020-03-31 237.95 $5.77 41.24
2019-12-31 218.95 $4.51 48.55
2019-09-30 169.42 $8.25 20.54
2019-06-30 183.38 $8.53 21.50
2019-03-31 183.95 $8.30 22.16
2018-12-31 165.71 $8.08 20.51
2018-09-30 192.74 $2.50 77.10
2018-06-30 169.96 $1.59 106.89
2018-03-31 162.98 $0.86 189.51
2017-12-31 149.86 $1.04 144.10
2017-09-30 152.04 $0.78 194.92
2017-06-30 128.87 $1.02 126.34
2017-03-31 109.35 $0.69 158.48
2016-12-31 73.67 $-0.47 0.00
2016-09-30 87.21 $-0.91 0.00
2016-06-30 86.02 $-1.13 0.00
2016-03-31 79.49 $-1.65 0.00
2015-12-31 125.83 $-2.31 0.00
2015-09-30 104.14 $-2.74 0.00
2015-06-30 123.48 $-3.07 0.00
2015-03-31 117.97 $-2.97 0.00
2014-12-31 118.80 $-3.14 0.00
2014-09-30 112.31 $-2.21 0.00
2014-06-30 94.68 $-2.03 0.00
2014-03-31 70.72 $-1.61 0.00
2013-12-31 74.30 $-2.04 0.00
2013-09-30 75.82 $-2.58 0.00
2013-06-30 80.06 $-2.31 0.00
2013-03-31 54.97 $-2.36 0.00
2012-12-31 41.90 $-0.50 0.00
2012-09-30 55.89 $0.59 94.73
2012-06-30 55.92 $1.88 29.74
2012-03-31 41.01 $1.34 30.60
2011-12-31 33.21 $0.04 830.25
2011-09-30 44.46 $-1.60 0.00
2011-06-30 51.99 $-3.66 0.00
2011-03-31 47.93 $-3.81 0.00
2010-12-31 35.03 $-3.77 0.00
2010-09-30 34.57 $-3.72 0.00
2010-06-30 32.90 $-3.52 0.00
2010-03-31 40.87 $-3.51 0.00
2009-12-31 42.85 $-3.72 0.00
2009-09-30 37.90 $-3.83 0.00
2009-06-30 35.97 $-3.92 0.00
2009-03-31 28.73 $-3.59 0.00
2008-12-31 30.38 $-3.27 0.00
2008-09-30 33.24 $-2.97 0.00
2008-06-30 33.47 $-2.86 0.00
2008-03-31 23.89 $-3.11 0.00
2007-12-31 23.23 $-3.03 0.00
2007-09-30 38.41 $-2.59 0.00
2007-06-30 28.56 $-2.23 0.00
2007-03-31 28.04 $-2.04 0.00
2006-12-31 37.42 $-1.87 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $47.610B $6.206B
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76